Literature DB >> 28696818

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Focused Update Guideline Summary.

Ian Krop1, Nofisat Ismaila1, Vered Stearns1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28696818     DOI： 10.1200/JOP.2017.024646

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  8 in total

1.  Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study.

Authors:  Una Kjällquist; Balazs Acs; Sara Margolin; Emelie Karlsson; Luisa Edman Kessler; Scarlett Garcia Hernandez; Maria Ekholm; Christine Lundgren; Erik Olsson; Henrik Lindman; Theodoros Foukakis; Alexios Matikas; Johan Hartman
Journal:  Cancers (Basel)       Date:  2022-05-25       Impact factor: 6.575

2.  The Effect of the New Eighth Edition Breast Cancer Staging System on 100 Consecutive Patients.

Authors:  Ashley Biswal; Jacqueline Erler; Omar Qari; Arthur A Topilow; Varsha Gupta; Mohammad A Hossain; Arif Asif; Brian Erler; Denise Johnson Miller
Journal:  J Clin Med Res       Date:  2019-05-10

3.  Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas.

Authors:  Seth B Sereff; Michael W Daniels; James L Wittliff
Journal:  J Clin Lab Anal       Date:  2019-07-29       Impact factor: 2.352

4.  Prognostic and Predictive Value of the American Joint Committee on Cancer Pathological Prognostic Staging System in Nodal Micrometastatic Breast Cancer.

Authors:  Jian Shi; Chen-Lu Lian; Feng Chi; Ping Zhou; Jian Lei; Li Hua; Jun Wang; Zhen-Yu He; San-Gang Wu
Journal:  Front Oncol       Date:  2020-12-18       Impact factor: 6.244

5.  Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry.

Authors:  Zohair Selmani; Chloé Molimard; Alexis Overs; Fernando Bazan; Loic Chaigneau; Erion Dobi; Nathalie Meneveau; Laura Mansi; Marie-Justine Paillard; Guillaume Meynard; Julien Viot; Marie-Paule Algros; Christophe Borg; Jean-Paul Feugeas; Xavier Pivot; Jean-Luc Prétet; Elsa Curtit
Journal:  Sci Rep       Date:  2022-03-07       Impact factor: 4.379

6.  A pharmacophore-based classification better predicts the outcomes of HER2-negative breast cancer patients receiving the anthracycline- and/or taxane-based neoadjuvant chemotherapy.

Authors:  Xuan Li; Hefen Sun; Qiqi Liu; Yang Liu; Yifeng Hou; Wei Jin
Journal:  Cancer Med       Date:  2021-06-02       Impact factor: 4.452

7.  Quality and reporting of clinical guidelines for breast cancer treatment: A systematic review.

Authors:  Marta Maes-Carballo; Luciano Mignini; Manuel Martín-Díaz; Aurora Bueno-Cavanillas; Khalid Saeed Khan
Journal:  Breast       Date:  2020-08-10       Impact factor: 4.380

Review 8.  Shared decision making in breast cancer treatment guidelines: Development of a quality assessment tool and a systematic review.

Authors:  Marta Maes-Carballo; Isabel Muñoz-Núñez; Manuel Martín-Díaz; Luciano Mignini; Aurora Bueno-Cavanillas; Khalid Saeed Khan
Journal:  Health Expect       Date:  2020-08-03       Impact factor: 3.377
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.